CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Cash flows from operating activities:
Net loss	$ (72,606)	$ (75,490)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization expense	279	826
Stock-based compensation expense	38,617	40,640
Accretion, net of amortization	(923)	(17)
Gain on investment	0	(12,394)
Premium deficiency reserve	(1,810)	(27,476)
Changes in operating assets and liabilities:
Accrued retrospective premiums	(49,798)	(22,758)
Other receivables	(695)	551
Surety bonds and deposits	20,481	(2,156)
Prepaid expenses	1,248	(11,934)
Other assets	3,391	876
Healthcare receivables	13,664	5,863
Non-Insurance receivable	(670)	(38)
Operating lease right-of-use assets	(84)	1,015
Unpaid claims	(924)	25,266
Accounts payable and accrued expenses	15,007	(678)
Accrued salaries and benefits	6,344	(3,557)
Deferred revenue	107,563	0
Other liabilities	694	(894)
Performance year obligation	(13,407)	(16,738)
Non-Insurance payable	12,751	43,230
Operating lease liabilities	(90)	(1,179)
Net cash provided by (used in) operating activities	79,032	(57,042)
Cash flows from investing activities:
Purchases of short-term investments, available-for-sale, and held-to-maturity securities	(67,893)	(113,079)
Proceeds from sales of short-term investments and available-for-sale securities	15,001	0
Proceeds from maturities of short-term investments, available-for-sale, and held-to-maturity securities	63,324	150,000
Purchases of property and equipment	(251)	(158)
Acquisition of Character Biosciences, Inc. Series A preferred shares	0	(250)
Net cash provided by investing activities	10,181	36,513
Cash flows from financing activities:
Issuance of common stock, net of early exercise liability	848	331
Treasury stock acquired	(2,982)	(5,939)
Net cash used in financing activities	(2,134)	(5,608)
Net (decrease) increase in cash, cash equivalents, and restricted cash	87,079	(26,137)
Cash, cash equivalents, and restricted cash, beginning of period	186,213	299,968
Cash, cash equivalents, and restricted cash, end of period	273,292	273,831
Reconciliation of cash and cash equivalents and restricted cash
Cash and cash equivalents	190,562	273,831
Restricted cash	82,730	0
Total cash, cash equivalents, and restricted cash	273,292	273,831
Supplemental disclosure of non-cash activities
Performance year receivable	(552,620)	(1,743,406)
Performance year obligation	552,620	1,743,406
Right-of-use assets obtained in exchange for lease liabilities	0	648
Recognition of equity method investments and preferred stock	0	8,644
Derecognition of noncontrolling interest	0	3,903
Conversion of Character Biosciences, Inc. convertible note to preferred stock	$ 0	$ 250